Table 1.

Prevalence and ratios of T-cell subsets in ankylosing spondylitis patients before and during infliximab (IFX) therapy.

Members of adaptive immunity	Healthy controls (n = 9)	Before IFX therapy (n = 13)	Week 2 after IFX therapy (n = 11)	Week 6 after IFX therapy (n = 8)
CD4+	35.80 [29.43-40.95]	42.7 [38.35–48.65]*	47.10 [43.00–49.10]*	44.30 [42.15–48.85]*
CD4+CD45RA+	49.50 [40.68–61.68]	50.80 [45.20–65.95]	50.90 [36.20–55.40]#	42.55 [39.55–60.78]#
CD4+CD25+	7.55 [6.20–7.88]	4.82 [4.22–5.42]*	3.92 [3.60–4.85]*	4.35 [4.04–4.98]*
CD4+CD69+	3.23 [2.83–4.48]	3.05 [2.72–3.28]	3.04 [2.69–3.43]	2.88 [2.21–3.36]
CD4+HLA-DR+	2.8 [2.53–3.81]	3.03 [2.09–3.46]	1.95 [1.56–2.33]	2.89 [2.21–3.51]
CD4+CD45RO+	42.95 [33.33–49.65]	41.50 [29.40–49.55]	45.50 [37.80–54.60]	47.45 [33.10–54.78]#
Th1	9.81 [8.95–12.53]	12.90 [11.75–13.80]*	14.00 [11.50–15.70]*	13.80 [12.43–18.83]*
Th2	4.54 [4.19–4.84]	9.18 [7.32–11.45]*	8.70 [7.98–11.30]*	10.90 [8.32–12.50]*
Th1/Th2 ratio	2.38 [1.95–2.64]	1.31 [1.06–1.85]*	1.40 [1.16–1.83]*	1.38 [1.11–1.72]*
Th17	0.69 [0.60–0.77]	1.18 [1.02–1.69]*	1.2 [0.84–1.55]*	1.26 [0.91–1.51]*
Treg	4.42 [3.76–5.58]	4.45 [3.57–5.51]	4.29 [3.66–5.72]	4.42 [4.05–5.24]
Th17/Treg ratio	0.14 [0.13–0.21]	0.27 [0.19–0.45]*	0.25 [0.17–0.39]*	0.29 [0.18–0.37]*
CD8+	18.00 [14.35–27.98]	17.70 [14.65–21.45]	18.30 [14.20–21.90]	16.65 [14.43–21.60]
CD8+CD45RA+	62.85 [53.38–75.78]	70.30 [61.70–78.75]	69.10 [55.20–72.50]	60.20 [54.43–70.33]
CD8+CD25+	2.84 [1.87–4.06]	2.81 [2.23–3.63]	2.85 [2.07–3.23]	3.29 [1.84–3.54]
CD8+CD69+	4.0 [3.53–12.78]	4.88 [3.37–5.89]	3.71 [3.26–6.77]	5.06 [3.55–6.27]
CD8+HLA-DR+	3.58 [3.10–5.31]	3.43 [2.95–4.33]	4.37 [2.93–5.15]	3.57 [2.91–5.15]
CD8+CD45RO+	23.65 [15.90–28.15]	19.40 [14.25–28.20]	26.30 [19.10–34.90]	28.45 [18.53–40.20]
CD4/CD8 ratio	2.07 [1.32–2.83]	2.26 [2.02–3.15]	2.61 [1.99–3.21]	2.82 [1.90–3.36]

Data are expressed as median [interquartile range] *versus control P < 0.05; ^#versus before IFX P < 0.05.